Announcing Full Approval and Expanded Indication

We are excited to announce the full approval of our non-immunosuppressive treatment for IgA nephropathy, and are grateful to the patient community, clinical trial investigators, patient advocacy organizations and all those who worked so hard to reach this milestone. Developing this medicine could not have been possible without the passion and collaboration of the rare kidney disease community.

 

Learn More

Pipeline

We are driven by science

The science we are advancing in rare kidney and metabolic disease has the potential to set new standards of care and bring hope to people with these rare disorders.

Learn More View Our Pipeline

THERAPEUTIC AREAS